{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:23:30Z","timestamp":1791401010574,"version":"4.3.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB841"],"award-info":[{"award-number":["SFB841"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis delta virus (HDV) infection causes severe liver disease which often leads to cirrhosis and hepatocellular carcinoma (HCC). Aim of this study was to establish the disease severity and prognostic factors for disease outcome by analysing frequencies of clinical events and their correlation with baseline virological and biochemical parameters as well as interferon and nucleos(t)ide analogue treatment choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied a single-centre cohort of 49 anti-HDAg-positive patients with HBsAg persistence for at least 6\u2009months. Virological and biochemical parameters, interferon and nucleos(t)ide analogue treatment choice as well as clinical events during follow-up were analysed by retrospective chart review (mean follow-up time 3\u2009years, range 0.25\u20137.67\u2009years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Severe clinical events occurred in 11\/49 hepatitis D patients, including HCC (8\/49), death (8\/49) or liver transplantation (2\/49). HCCs only occurred secondary to liver cirrhosis and their event rates in this cohort of hepatitis D patients did not differ from a matched HBV mono-infected cohort with comparable frequency of liver cirrhosis. A stepwise multivariate logistic regression revealed low platelet count (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090. 0290) and older age (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0337) correlating most strongly with overall clinical events, while serum HDV RNA positivity at baseline did not correlate with any clinical outcome. Interferon-free but not nucleos(t)ide analogue-free patient care correlated with the occurrence of HCC at logistic regression, although only 3\/18 interferon-treated patients demonstrated repeatedly negative HDV PCR results post therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data indicate that progressive liver disease at baseline plays a major role as predictive factor for overall clinical outcome of hepatitis D patients. In particular, HCC risk may not be underestimated in hepatitis D virus RNA negative hepatitis D patients with advanced liver fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-020-1168-9","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T10:03:38Z","timestamp":1580378618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["High rates of cirrhosis and severe clinical events in patients with HBV\/HDV co-infection: longitudinal analysis of a German cohort"],"prefix":"10.1186","volume":"20","author":[{"given":"Jan-Hendrik","family":"Bockmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Grube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Landahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Wehmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Giersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela T.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Dandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"L\u00fcth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"L\u00fctgehetmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Schulze Zur Wiesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"3","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","volume":"68","author":"Hai-Yan Chen","year":"2018","unstructured":"Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018;68:512\u201321.","journal-title":"Gut"},{"issue":"3","key":"1168_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/s-0032-1323628","volume":"32","author":"P Farci","year":"2012","unstructured":"Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32(3):228\u201336.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"1168_CR3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2893.2010.01324.x","volume":"18","author":"M Buti","year":"2011","unstructured":"Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, Sauleda S, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18(6):434\u201342.","journal-title":"J Viral Hepat"},{"issue":"1 Suppl","key":"1168_CR4","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","volume":"64","author":"C Sureau","year":"2016","unstructured":"Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. 2016;64(1 Suppl):S102\u201316.","journal-title":"J Hepatol"},{"issue":"5","key":"1168_CR5","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","volume":"136","author":"R Romeo","year":"2009","unstructured":"Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of Hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629\u201338.","journal-title":"Gastroenterology."},{"issue":"5","key":"1168_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","volume":"53","author":"GA Niro","year":"2010","unstructured":"Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53(5):834\u201340.","journal-title":"J Hepatol"},{"issue":"6","key":"1168_CR7","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","volume":"130","author":"CW Su","year":"2006","unstructured":"Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130(6):1625\u201335.","journal-title":"Gastroenterology"},{"issue":"3","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-0032-1323629","volume":"32","author":"C Yurdaydin","year":"2012","unstructured":"Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32(3):237\u201344.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hep.27102","volume":"60","author":"B Heidrich","year":"2014","unstructured":"Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60(1):87\u201397.","journal-title":"Hepatology"},{"issue":"4","key":"1168_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa0912696","volume":"364","author":"H Wedemeyer","year":"2011","unstructured":"Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1168_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/hep.28876","volume":"65","author":"Anika Wranke","year":"2016","unstructured":"Wranke A, Calle Serrano B, Heidrich B, Kirschner J, Bremer B, Lehmann P, et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2016;65(2):414\u201325.","journal-title":"Hepatology"},{"issue":"7","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","volume":"126","author":"P Farci","year":"2004","unstructured":"Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126(7):1740\u20139.","journal-title":"Gastroenterology"},{"issue":"5","key":"1168_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.07.005","volume":"59","author":"EK Manesis","year":"2013","unstructured":"Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949\u201356.","journal-title":"J Hepatol"},{"issue":"1","key":"1168_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PAUL R. ROSENBAUM","year":"1983","unstructured":"Rosenbaum PRR, Donald B. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"2","key":"1168_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"7","key":"1168_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/jmv.25438","volume":"91","author":"Lucio Boglione","year":"2019","unstructured":"Boglione L, Lupia T, Cariti G, Ghisetti V, Milia MG, Burdino E, et al. Antiviral treatment with PEG-IFN and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: a retrospective analysis. J Med Virol. 2019;91(7):1329\u201334.","journal-title":"Journal of Medical Virology"},{"issue":"7","key":"1168_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/v9070172","volume":"9","author":"Florian Lempp","year":"2017","unstructured":"Lempp FA, Urban S. Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen. Viruses. 2017;9(7):172.","journal-title":"Viruses"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-1168-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-020-1168-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-1168-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T19:09:19Z","timestamp":1611860959000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-1168-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-1168-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"8 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics board and classified as a retrospective chart review study, no informed consent was required (Ethik-Kommission der \u00c4rztekammer Hamburg, WF-035\/17).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JSZW has previously served as a speaker for Roche and Gilead.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}